Grant received in 2021
DCCC has funded 129.430 DKK to the project
Patients with advanced estrogen receptor positive and human epidermal receptor-2 normal metastatic breast cancer are offered endocrine therapy combined with an inhibitor of the cyclin-dependent kinase 4 and 6 (CDK4/6). This treatment was approved in 2017 in Denmark. The optimal treatment following disease progression on CDK4/6 inhibitor treatment combined with endocrine therapy is undetermined.
The purpose of this study is to investigate if patients continuing CDK4/6 inhibitors following progression can obtain a longer progression free survival (PFS) and overall survival (OS) compared to the 2. line endocrine therapy offered as standard treatment.
The study will be conducted as a national, open, randomized phase 3 study and will include patients who are candidates for continued endocrine therapy following progression on a CDK4/6 inhibitor. The study will originate from the Danish Breast Cancer Group (DBCG) and data will be collected in the DBCG database for recurrent disease.
Multidisciplinary organisation
The study is related to Danish Breast Cancer Group (DBCG), and will be conducted across all oncological departments in Denmark
Project stakeholders
- Iben Kümler, Specialty Registrar, Clinical Associate Professor, PhD, Depart. of Oncology, Herlev Hospital, member of the steering group for DBCG's recurrence database. Primary contact, e-mail: ibekml01@regionh.dk
- Bent Ejlertsen, Professor, Consultant, Depart. of Oncology, Rigshospitalet, medical director of DBCG as well as a member of the steering group for DBCG's recurrence database
- Ann Knop, Consultant, Depart. of Oncology, Rigshospitalet, Chairman of DBCG and member of the steering group for DBCG's recurrence database
- Dorte Nielsen, Professor, Consultant, Depart. of Oncology, Herlev Hospital, member of the steering group for DBCG's recurrence database
- Tobias Berg, MD, PhD student at DBCG, member of the steering group for DBCG's recurrence database
- Maj-Britt Raaby Jensen, Chief statistician, DBCG,member of the steering group for DBCG's recurrence database. Medical Committee under DBCG which represents all oncology departments in Denmark.
- Sigen Borgquist, Professor, Consultant, Depart. of Oncology, Århus Universitetshospital
- Jeanette Dupont Jensen, Consultant, Depart. of Oncology, Odense University Hospital
- Erik Hugger Jakobsen, Depart. of Oncology, Vejle Hospital & Esbjerg Hospital
- Hella Danø, Depart. of Oncology, North Zealand University Hospital,
- Vesna Glavicic, Depart. of Oncology, Næstved Hospital
- Julia Kenholm Consultant, Depart. of Oncology, Herning Hospital
- Sofie Yammeni, Consultant, Depart. of Oncology, Ålborg University Hospital
- Ditte Hygum-Nielsen, Consultant, Department of Medical Diseases, Bornholms Hospital